Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (Anti-Lag-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin LymphomaNathalie A. Johnson,David Lavie,Peter Borchmann,Gareth P. Gregory,Alex F. Herrera,Leonard Minuk,Vladan Vucinic,Philippe Armand,Abraham Avigdor,Robin Gasiorowski,Yair Herishanu,Colm Keane,John Kuruvilla,John Palcza,Pallavi Pillai,Akash Nahar,John TimmermanBLOOD（2022）引用 1|浏览23AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
